306 related articles for article (PubMed ID: 32100585)
21. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
22. An evaluation of encorafenib for the treatment of melanoma.
Carr MJ; Sun J; Eroglu Z; Zager JS
Expert Opin Pharmacother; 2020 Feb; 21(2):155-161. PubMed ID: 31790307
[No Abstract] [Full Text] [Related]
23. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
24. Encorafenib and Binimetinib: First Global Approvals.
Shirley M
Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
[TBL] [Abstract][Full Text] [Related]
25. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Ohuchi K; Hashimoto A; Aiba S
J Dermatol; 2020 Jun; 47(6):654-657. PubMed ID: 32293049
[TBL] [Abstract][Full Text] [Related]
26. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
27. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
28. Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
Ngo P; Bycroft R
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527213
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
30. In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
Flaherty K
Clin Adv Hematol Oncol; 2017 Oct; 15(10):745-747. PubMed ID: 29040252
[No Abstract] [Full Text] [Related]
31. Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
Turner MC; Rossfeld K; Salama AK; Tyler D; Beasley G
Expert Opin Pharmacother; 2017 Apr; 18(5):487-495. PubMed ID: 28277830
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
33. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
34. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
35. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
Di Guardo L
Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129
[TBL] [Abstract][Full Text] [Related]
37. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
38. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230
[TBL] [Abstract][Full Text] [Related]
39. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
Schreck KC; Strowd RE; Nabors LB; Ellingson BM; Chang M; Tan SK; Abdullaev Z; Turakulov R; Aldape K; Danda N; Desideri S; Fisher J; Iacoboni M; Surakus T; Rudek MA; Bettegowda C; Grossman SA; Ye X
Clin Cancer Res; 2024 May; 30(10):2048-2056. PubMed ID: 38446982
[TBL] [Abstract][Full Text] [Related]
40. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
